Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Science (New York, N.Y.)|February 27, 2016
Structural and molecular basis for Ebola virus neutralization by protective human antibodiesJohn Misasi, Morgan S A Gilman, Masaru Kanekiyo, et al.
Plos Pathogens|April 8, 2021
High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19Sung Hee Ko, Elham Bayat Mokhtari, Prakriti Mudvari, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2021
High-Throughput, Single-Copy Sequencing Reveals SARS-CoV-2 Spike Variants Coincident with Mounting Humoral Immunity during Acute COVID-19Sung Hee Ko, Elham Bayat Mokhtari, Prakriti Mudvari, et al.
Cell Reports. Medicine|March 2, 2022
SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivitySimone I Richardson, Nelia P Manamela, Boitumelo M Motsoeneng, et al.
Biorxiv : the Preprint Server for Biology|January 12, 2022
Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through OmicronI-Ting Teng, Alexandra F Nazzari, Misook Choe, et al.
Plos One|May 24, 2022
Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through OmicronI-Ting Teng, Alexandra F Nazzari, Misook Choe, et al.
Science (New York, N.Y.)|March 24, 2022
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529Tongqing Zhou, Lingshu Wang, John Misasi, et al.
Lancet (London, England)|January 29, 2019
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 studyMartin R Gaudinski, Emily E Coates, Laura Novik, et al.
Science (New York, N.Y.)|February 27, 2016
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibodyDavide Corti, John Misasi, Sabue Mulangu, et al.
The American Journal of Tropical Medicine and Hygiene|February 10, 2026
Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D VaccineMatheus O de Souza, Danielle R D Saunders, Andrew Miller, et al.
Pageof 4